IP78-12: Nivolumab plus Cabozantinib versus Pembrolizumab plus Lenvatinib for Metastatic Renal Cell Carcinoma: A Propensity Score-matched Analysis of Japanese Multicenter Database
Monday, May 18, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)
147B
Abstract